Clinical Trial Finder

Key

Inclusion Criteria:

All participants. 1. Age ≥ 18 years old. 2. Confirmed diagnosis of glioblastoma (WHO Grade IV). 3. Agreement to provide archival tumor tissue for exploratory biomarker analysis. 4. Ability to undergo serial MRIs. 5. Eastern Cooperative Oncology Group (ECOG) status ≤ 1. 6. Adequate hematologic and end-organ function. 7. Females of childbearing potential and non-sterile males must agree to use highly effective methods of birth control throughout the course of study and at least up to 6 months after last dosing. 8. Ability to swallow whole capsules. Participants in Arms A and B (not Arm C) must meet inclusion criteria # 9

• - 11: 9.

No previous treatment for GBM except surgery. 10. Able to start radiation therapy ≤ 49 days after surgery but ≥ 14 days after a biopsy or ≥28 days after an open biopsy or craniotomy with adequate wound healing. 11. Documented unmethylated MGMT promoter status. Participants in Arm C Escalation (Phase 1b) must meet inclusion criteria # 12

• - 15: 12.

Documentation of MGMT promoter status. 13. No prior systemic chemotherapy other than TMZ for GBM. 14. Histologically confirmed secondary glioblastoma. 15. Disease that is evaluable or measurable as defined by Response Assessment in Neuro-Oncology (RANO) criteria. Participants in Arm C Expansion (Phase 2), must meet criteria # 16

• - 18: 16.

Histologically confirmed de novo (primary) glioblastoma with unequivocal first progressive disease (PD) after RT with concurrent/adjuvant TMZ chemotherapy. 17. Disease that is measurable as defined by RANO criteria. 18. Documentation of MGMT promoter status.Key

Exclusion Criteria:

All participants. 1. Prior chemotherapy, biologic therapy, immunotherapy or investigational agents ≤21 days prior to start of study treatment. 2. Toxicity of ≥ Grade 2 from prior therapy. 3. Major surgery or significant other injury ≤ 4 weeks prior to start of study treatment. 4. History of other active malignancies within 2 years with exception of (i) adequately treated in situ cancer of the cervix, (ii) non-melanoma skin cancer, or (iii) localized adequately treated cancer with curative intent or malignancy diagnosed > 2 years ago with no evidence of disease and no treatment ≤ 2 years prior to study treatment. 5. Active infection requiring systemic treatment. 6. Known human immunodeficiency virus (HIV) or active viral hepatitis. 7. Active, clinically significant cardiac disease or any Class 3 or 4 cardiac disease, ventricular arrhythmia or Cerebrovascular Accident (CVA) ≤ 6 months prior to start of treatment. 8. Active clinically significant gastrointestinal disease. 9. Active bleeding disorder ≤ 6 months prior to start of treatment. 10. Need for therapeutic anti-coagulation with heparin, warfarin or other anticoagulants. 11. Use of any medications or food known to be strong or moderate cytochrome P450, family 3, subfamily A (CYP3A) inhibitors or strong inducers. 12. Pregnant or nursing females. 13. Significant intercurrent illness that may result in participant's death prior to death from glioblastoma. Arms B and C Only: 14. Known hypersensitivity to any component of TMZ or decarbazine (DTIC). 15. Have hereditary problems of galactose intolerance.NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

An open-label, multiple-dose, dose-escalation study to determine the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of Pamiparib in combination with radiation therapy (RT) and/or TMZ. In dose escalation/Phase 1b, Pamiparib will be combined with RT (Arm A) or RT and TMZ (Arm B) in participants with newly diagnosed unmethylated glioblastoma (GBM) and in Arm C of the study Pamiparib will be combined with TMZ in participants with methylated or unmethylated recurrent/refractory GBM. The dose expansion/Phase 2 phase will enroll up to 4 cohorts: participants with newly diagnosed unmethylated GBM in Arms A and B, and 2 cohorts of participants with recurrent/refractory GBM grouped by O-6-methylguanine-DNA methyltransferase (MGMT) status

• - unmethylated or methylated - in Arm C.

Participants in Arms A and B are treated until completion of RT and participants in Arm C may continue treatment in the absence of safety concerns and disease progression.

Arms

Experimental: Arm A (Dose Escalation)

Participants with newly diagnosed unmethylated GBM will receive Pamiparib and radiation therapy.

Experimental: Arm B (Dose Escalation)

Participants with newly diagnosed unmethylated GBM will receive Pamiparib, radiation therapy (RT) and temozolomide (TMZ).

Experimental: Arm A (Dose Expansion)

Participants with newly diagnosed unmethylated GBM will receive Pamiparib and radiation therapy.

Experimental: Arm C (Dose Escalation)

Participants with recurrent/refractory methylated or unmethylated GBM will receive Pamiparib and TMZ.

Experimental: Arm C (Dose Expansion-Cohorts C1 and C2)

Participants with recurrent/refractory methylated or unmethylated GBM will receive Pamiparib and TMZ.

Interventions

Drug: - Pamiparib

Administered as specified in the treatment arm

Drug: - TMZ

Administered as specified in the treatment arm

Radiation: - Radiation

Up to 60 Gy (total) over 6 - 7 weeks